myelopathi
albeit
low
diseas
penetr
infect
present
healthi
individu
would
otherwis
qualifi
donor
transfus
transmiss
document
attend
diseas
burden
poorli
character
wake
event
caus
anoth
retroviru
hiv
antibodi
test
requir
unit
state
controversi
impact
costeffect
persist
last
year
addit
nonspecif
measur
deploy
further
transfus
safeti
includ
stringent
process
control
unit
state
current
good
manufactur
practic
cgmp
code
feder
regul
prevent
distribut
transfus
blood
unaccept
donor
donat
manag
enter
suppli
chain
develop
deploy
ever
complex
inform
system
clear
food
drug
administr
medic
devic
blood
establish
comput
system
requir
support
kind
qualiti
system
final
litani
real
purport
advers
outcom
attend
transfus
infecti
also
seriou
noninfecti
hazard
clinic
cascad
ultim
expos
patient
transfus
scrutini
rubric
patient
blood
manag
approach
contribut
impress
safeti
transfus
recogn
infect
develop
world
pathogen
reduct
process
labil
blood
compon
proactiv
solut
remain
aspir
yet
avail
compon
potent
agent
consensu
health
econom
justif
pathogen
reduct
absent
view
societ
perspect
overlay
histori
classic
pathogen
new
pathogen
emerg
discoveri
identif
new
agent
acceler
number
viral
speci
recogn
infect
human
predict
rise
less
larg
major
increas
sinc
fig
reason
divers
beyond
scope
chapter
shrink
globe
put
pathogen
subsaharan
rain
forest
within
h
blood
center
northern
plain
urban
especi
combin
poverti
overcrowd
human
chang
encroach
divers
ecolog
nich
chang
host
pathogen
vector
relationship
alter
climat
anim
husbandri
also
affect
reservoir
pathogen
vector
distribut
new
discoveri
system
like
nextgener
sequenc
metagenom
identifi
potenti
pathogen
environ
wildlif
reservoir
human
microbiom
well
diseas
associ
even
consid
social
media
via
internet
bring
us
nearli
instantan
news
specul
new
diseas
outbreak
anywher
world
integr
decid
potenti
threat
blood
safeti
regim
difficult
task
transfus
medicin
commun
choos
proactiv
framework
within
approach
emerg
infect
despit
initi
incomplet
inform
impact
transfus
safeti
wnv
sever
acut
respiratori
syndrom
coronaviru
sarscov
trypanosoma
cruzi
zika
babesia
microti
recent
demonstr
zoonot
infect
emerg
emerg
conscious
becom
target
intervent
mani
zoonot
andor
arthropodborn
agent
implement
mitig
measur
beyond
requir
donor
well
give
need
think
includ
mean
restrict
dengu
chikungunya
merscov
nipah
hendra
sever
fever
thrombocytopenia
syndrom
viru
sftsv
bourbon
powassan
virus
mayoro
viru
tickborn
agent
erlichia
sp
anaplasma
phagocytophilum
leishmania
agent
persist
arthropod
andor
nonhuman
vertebr
reservoir
spillov
human
popul
either
contact
vector
transmiss
tickborn
infect
consid
herein
year
discoveri
zoonot
infect
exclud
hiv
certainli
less
clinic
impact
transfus
medicin
classic
sexual
parenter
transmit
agent
especi
epidem
scenario
sever
present
promin
convers
interven
blood
safeti
context
taken
specul
need
intervent
pathogen
transfus
transmiss
asymptomat
presenc
agent
biolog
plausibl
theoret
inde
proactiv
contrast
histor
approach
risk
respons
consumpt
scarc
resourc
none
appropri
best
light
precaution
perfect
world
answer
four
question
put
transfusiontransmit
agent
recipi
infect
prospect
inform
consider
develop
deploy
mitig
strategi
agent
present
blood
otherwis
qualifi
donor
agent
parenter
transmiss
blood
organtissu
transplant
transmiss
biolog
plausibl
agent
surviv
contemporari
blood
compon
transmit
agent
transmit
pose
materi
clinic
risk
transfusiondo
caus
signific
ill
among
suscept
transfus
recipi
unfortun
current
surveil
pathogen
discoveri
techniqu
increasingli
interconnect
world
answer
question
avail
incomplet
decisionmak
must
startedthat
initi
respons
necessarili
consid
precautionari
context
question
correct
process
ought
select
agent
examin
risk
report
transfus
transmiss
come
light
unansw
sever
histor
exampl
provid
describ
actual
approach
pathogen
vcjd
zoonot
transmiss
spongiform
encephalopathi
tse
spread
bovin
human
mainli
unit
kingdom
precautionari
deferr
requir
recognit
transfus
transmiss
base
larg
occurr
tse
sporad
cjd
kuru
et
al
human
presenc
vcjd
prion
reticuloendotheli
system
appar
foodborn
human
case
preced
parenter
transmiss
prion
caus
classic
sporad
cjd
deferr
aim
prevent
advers
outcom
proven
rare
even
unit
kingdom
epicent
bovin
spongiform
encephalopathi
epidem
cost
ongo
loss
mani
thousand
donor
resid
travel
transfus
countri
risk
addit
difficult
donor
counsel
session
estim
donor
loss
rang
high
unit
state
like
maintain
concern
theoret
subsequ
wave
vcjd
epidem
larg
relat
incub
period
associ
polymorph
human
prion
protein
gene
adjud
mitig
strategi
mosquitoborn
avian
pathogen
wnv
implement
recognit
singl
transmiss
viru
blood
donor
organ
donor
forward
organ
recipi
emerg
respons
ramp
sever
week
use
incomplet
understand
level
risk
address
base
clinic
inform
case
model
data
produc
observ
transmiss
twentythre
blood
recipi
infect
document
retrospect
first
season
context
wnv
case
report
cdc
within
less
year
first
case
report
minipool
nucleic
acid
test
develop
implement
across
us
blood
suppli
subsequ
season
strategi
trigger
individu
donat
test
increas
sensit
evolv
despit
persist
endem
activ
unit
state
transfus
transmiss
wnv
essenti
elimin
sarscov
envelop
rna
viral
respiratori
pathogen
zoonot
origin
caus
signific
mortal
first
identifi
asia
spread
asia
north
america
sporad
travelassoci
case
subsequ
extens
local
healthcareassoci
nosocomi
transmiss
sar
met
fda
guidanc
immedi
implement
requir
interrog
us
blood
donor
histori
sar
potenti
exposur
case
travel
resid
area
day
present
donat
temporari
deferr
requir
risk
present
base
theoret
possibl
asymptomat
viremia
isol
viru
tissu
outsid
respiratori
tract
presum
result
bloodborn
spread
intervent
occur
absent
clinic
evid
parenter
transfus
risk
sarscov
rna
subsequ
found
patient
plasma
earli
day
onset
symptom
still
data
infecti
viremia
incub
period
among
asymptomat
contact
case
judg
plausibl
parenter
transmiss
requir
donor
screen
allow
laps
day
cdc
lift
last
travel
alert
sar
reemerg
ebola
recogn
spread
anim
reservoir
human
unpredict
massiv
west
african
ebola
outbreak
result
promulg
fda
guidanc
prevent
transfus
transmiss
pathogen
recogn
transmit
rout
respons
predic
observ
viru
present
blood
bodi
fluid
direct
contact
associ
highli
morbid
infect
zika
viru
nonhuman
primat
viru
spill
human
popul
caus
pandem
cover
elsewher
exampl
bear
repetit
nucleic
acid
present
blood
asymptomat
individu
includ
donor
us
donor
frequent
travel
affect
area
outsid
mainland
unit
state
major
vector
present
area
mainland
unit
state
sexual
transmiss
document
poorli
quantit
rout
infect
driven
recognit
sever
clinic
outcom
among
infant
infect
utero
neurolog
morbid
proport
infect
adult
investig
individualdon
nucleic
acid
screen
zika
viru
implement
emerg
unit
state
absent
evid
clinic
signific
morbid
associ
receipt
blood
virem
donor
write
three
appar
transfus
transmiss
viru
publish
brazil
none
caus
recogniz
morbid
cdc
investig
estim
cost
emerg
implement
zika
screen
us
collect
facil
annual
interest
exampl
intervent
requir
wide
implement
voluntarili
list
mean
exhaust
potenti
pathogen
act
exampl
chosen
epidem
pathogen
somewher
exemplifi
difficulti
face
tri
assess
risk
transfusiontransmit
infect
particular
refer
four
question
aed
mosquito
transmit
dengu
flaviviru
chikungunya
alphaviru
caus
explos
epidem
primarili
tropic
subtrop
region
develop
world
manifest
asymptomat
viremia
vectorborn
infect
associ
morbid
case
dengu
mortal
larg
global
area
affect
dengu
chikungunya
overlap
endem
malaria
temporari
malaria
deferr
travel
area
sure
provid
partial
protect
blood
suppli
unaffect
area
howev
use
malaria
deferr
clearli
incomplet
approach
fail
address
risk
associ
malariafre
area
autochthon
transmiss
unit
state
nonendem
countri
compet
vector
establish
eg
seen
sporad
dengu
unit
state
dengu
strictli
zoonot
sylvan
nonhuman
primatemosquito
cycl
addit
urban
humanmosquito
cycl
respons
human
epidem
respons
dengu
risk
lack
thereof
inform
consider
use
address
emerg
pathogen
common
human
arbovir
infect
world
recent
estim
suggest
million
infect
occur
annual
human
infect
rang
asymptomat
lethal
hemorrhag
fever
increas
incid
worldwid
transfus
transmiss
document
albeit
infrequ
accordingli
dengu
label
prioriti
agent
aabb
transfusiontransmit
diseas
committe
exercis
howev
date
intervent
serious
consid
unit
state
beyond
requir
donor
well
bled
contribut
malaria
deferr
donor
risk
dengu
travel
outbreak
identifi
prior
donat
manag
strategi
temporarili
restrict
donat
use
current
investig
donor
screen
test
consid
use
variabl
cost
impact
avail
donor
recent
data
use
nucleic
acid
amplif
test
suggest
clinic
burden
transfus
transmiss
may
quit
modest
requir
action
studi
brazil
suscept
transfus
recipi
blood
dengu
rnaposit
donor
clinic
indistinguish
suscept
control
five
expos
recipi
experienc
probabl
dengu
transmiss
one
possibl
infect
surveil
clinic
sequela
transfus
transmiss
clearli
prioriti
blood
commun
consid
relev
viru
chikungunya
origin
africa
histor
circul
sylvan
cycl
among
forestdwel
aed
mosquito
nonhuman
primat
occasion
human
spillov
human
infect
gener
symptomat
thought
benign
howev
recent
pandem
occurr
sever
joint
pain
persist
mani
week
month
recogn
mutat
viral
envelop
protein
allow
adapt
highlevel
replic
cosmopolitan
vector
aed
albopictu
subsequ
viru
emerg
africa
pandem
spread
across
indian
ocean
asia
pacif
start
reach
america
st
martin
caribbean
late
explos
attack
rate
epidem
reunion
island
indian
ocean
met
suspens
collect
red
blood
cell
plasma
island
import
metropolitan
franc
emerg
introduct
pathogen
reduct
platelet
collect
local
atrisk
donor
viru
transmit
iv
inocul
monkey
model
exercis
suggest
substanti
risk
transmiss
blood
donor
test
caribbean
use
nucleic
acid
test
identifi
test
donor
rnaemic
posit
unit
discard
prospect
test
delink
recipi
outcom
avail
intern
spread
america
case
report
pan
american
health
organ
midseptemb
transfus
transmiss
neither
recogn
alleg
transfus
medicin
intervent
plan
unit
state
beyond
continu
surveil
limit
local
transmiss
south
florida
provok
scale
respons
depend
case
load
monitor
conjunct
local
public
health
addit
travel
deferr
potenti
exposur
epidem
exu
proactiv
donat
quarantin
zip
code
autochthon
case
callback
assur
donor
remain
well
compon
could
distribut
transfus
zip
codebas
stage
cessat
collect
local
case
beyond
predetermin
threshold
number
absenc
recogn
alleg
transfusionassoci
morbid
two
virus
may
result
sever
thing
may
nearli
imposs
recogn
event
background
epidem
vectorborn
transmiss
especi
transfus
cohort
might
risk
sourc
nonepidem
locat
diagnosi
may
never
consid
clinician
unfamiliar
potenti
parenter
transmiss
infect
clinic
nonspecif
patient
ill
enough
requir
transfus
may
multipl
sourc
fever
experi
infecti
diseas
clinician
febril
patient
gener
ask
recent
transfus
histori
ie
clinic
surveil
passiv
limit
final
import
pathogen
differ
mosquito
transmiss
parenter
transmiss
relat
effect
arthropod
mediat
inject
viru
innat
immun
inflammatori
respons
associ
vector
transmiss
pathogen
reduct
techniqu
develop
labil
compon
like
effect
virus
likewis
multipl
step
manufactur
plasma
deriv
make
risk
de
minimi
includ
wet
heat
dri
heat
lyophil
solventdeterg
treatment
nanofiltr
purif
step
use
manufactur
plasmaderiv
medicin
product
includ
cold
ethanol
chemic
precipit
chromatograph
step
mitig
risk
contrast
sarscov
intervent
requir
respons
merscov
envelop
rna
betacoronaviru
emerg
human
pathogen
report
subsequ
countri
infect
endem
arabian
peninsula
larg
major
case
occur
origin
case
occasion
export
elsewher
merscov
caus
respiratori
infect
includ
pneumonia
respiratori
failur
incub
period
day
week
gastrointestin
sign
symptom
may
also
occur
treatment
support
effect
prophylact
measur
describ
symptomat
merscov
infect
associ
highmort
respiratori
ill
human
asymptomat
infect
relev
concern
transfus
recogn
aggress
laboratori
investig
contact
case
infect
certainli
consider
less
lethal
mortal
report
recogn
diseas
emerg
septemb
laboratoryconfirm
case
report
kingdom
saudi
arabia
mild
symptom
sever
diseas
die
two
import
infect
recogn
unit
state
affect
healthcar
worker
expos
saudi
arabia
potenti
extens
transmiss
outsid
endem
area
exemplifi
larg
outbreak
healthcareassoci
infect
south
korea
link
case
index
patient
travel
middl
east
ultim
reservoir
establish
agent
like
evolv
bat
transmit
camel
direct
contact
dromedari
camel
consumpt
raw
camel
milk
suspect
epidemiolog
rout
primari
infect
merscov
transmiss
human
secondari
case
predominantli
healthcar
set
absenc
nonadher
standard
infect
prevent
control
strategi
transfus
transmiss
merscov
neither
report
suspect
date
preced
coronavirus
occurr
asymptomat
infect
obvious
problemat
howev
evid
viremia
rare
sought
evalu
date
confin
sever
ill
patient
index
patient
famili
cluster
tunisia
viral
sequenc
amplifi
pcr
serum
week
ill
anoth
patient
fatal
infect
sequenc
detect
week
onset
ill
appar
test
earlier
neither
case
infecti
viru
sought
one
hundr
ten
saudi
blood
donor
seroneg
neutral
antibodi
systemat
studi
look
asymptomat
rnaemia
viremia
higherrisk
cohort
contact
case
recent
formal
merscov
risk
assess
includ
mention
risk
transfusiontransmit
infect
european
cdc
rapid
risk
assess
communic
diseas
risk
associ
hajj
given
low
number
case
outsid
middl
east
appar
requir
close
contact
ill
patient
persontoperson
transmiss
occur
esp
healthcar
worker
appear
specif
travel
risk
deferr
appropri
continu
monitor
ie
systemat
horizon
scan
chang
epidemiolog
clinic
patholog
mer
alert
chang
would
suggest
risk
parenter
spread
transfus
risk
seem
appropri
respons
aabb
ttd
emerg
infect
work
group
reject
use
specif
screen
question
referenc
fda
guidanc
sar
donor
spontan
provid
histori
exposur
ill
donor
provid
inform
screen
deferr
criteria
use
sar
day
last
exposur
day
complet
treatment
resolut
ill
seem
ration
wholli
empir
riboflavin
ultraviolet
light
amotosalen
ultraviolet
light
report
inactiv
log
merscov
plasma
data
platelet
rbc
whole
blood
avail
manufactur
step
use
plasma
deriv
render
medicin
safe
nipah
hendra
appar
nonpathogen
cedar
viru
henipavirus
paramyxovirina
famili
current
confin
south
asia
australia
fig
nipah
emerg
bat
zoonosi
spill
human
caus
human
infect
rang
inappar
lethal
enceph
envelop
rna
viru
share
amino
acid
homolog
across
region
genom
hendra
viru
nipah
emerg
malaysia
bat
infect
swine
swine
infect
human
outbreak
enceph
respiratori
ill
approxim
human
case
death
clinic
spectrum
seem
variabl
across
geograph
separ
outbreak
treatment
support
antivir
ribavirin
use
uncontrol
circumst
success
effect
prophylaxi
medic
immunoglobulin
vaccin
report
human
incub
period
rang
day
month
day
variat
accord
locat
outbreak
direct
contact
respiratori
secret
infect
swine
gener
mild
ill
appar
infect
consumpt
mango
contamin
bat
urin
sourc
index
outbreak
bat
genu
pteropu
fli
fox
appear
natur
reservoir
infect
varieti
mammalian
secondari
host
ie
felin
canin
swine
equin
outbreak
bangladesh
associ
consumpt
date
palm
sap
contamin
infect
bat
direct
contact
infect
bat
may
also
result
transmiss
humantohuman
transmiss
includ
famili
healthcar
associ
document
indirect
evid
ie
lack
viru
isol
nucleic
acid
test
reactiv
latent
chronic
infect
result
recurr
cn
diseas
death
despit
recurr
outbreak
especi
bangladesh
india
alleg
transfus
transmiss
littl
attent
paid
implic
blood
safeti
hendra
viru
close
relat
nipah
sequenc
level
recogn
human
hendra
viru
infect
much
rarer
nipah
seven
case
four
death
recogn
sinc
first
equin
outbreak
australia
hors
infect
contact
infect
urin
pteropu
bat
total
outbreak
equin
respiratori
ill
involv
hors
confin
northeast
coast
australia
evid
infect
emerg
serolog
studi
number
vertebr
invertebr
repositori
sampl
caus
spectrum
human
ill
nonspecif
fever
flulik
syndrom
fatal
enceph
gener
consequ
spillov
equin
infect
treatment
support
effect
prophylaxi
avail
incub
period
day
exposur
transmiss
human
occur
mainli
direct
contact
care
sick
hors
time
autopsi
earli
studi
recipi
hors
infect
intraven
use
homogen
spleen
lung
two
index
hors
postmortem
lung
liver
kidney
spleen
human
deced
infecti
tissu
cultur
one
case
cn
infect
patient
recov
recurr
neurolog
ill
year
later
die
report
alleg
transfus
transmiss
small
amount
evid
acut
lowlevel
viremia
nipah
viru
one
might
expect
hendra
patholog
studi
demonstr
respiratori
vascular
endotheli
cell
import
target
nipah
hendra
spread
portal
entri
like
respiratori
epithelium
fulli
character
later
stage
clinic
infect
pulmonari
endothelium
infect
small
vessel
vascul
ensu
believ
enter
bloodstream
point
dissemin
free
cellassoci
viru
gain
entri
central
nervou
system
least
one
mous
model
discount
requir
viremia
develop
enceph
hendra
direct
evid
human
viremia
provid
either
viru
whether
asymptomat
infect
individu
sustain
potenti
infecti
viremia
address
blood
donor
studi
publish
donor
screen
whether
health
histori
vitro
assay
propos
either
virus
donor
question
understand
exposur
risk
develop
implement
need
event
outbreak
might
affect
blood
donor
highthroughput
assay
avail
although
diagnost
assay
might
repurpos
indic
need
aros
donor
deferr
strategi
histori
exposur
infect
necessarili
empir
histori
exposur
would
multipl
maximum
credibl
incub
period
eg
perhap
week
hendra
month
nipah
sinc
proport
infect
asymptomat
donor
reentri
neg
diagnost
serolog
might
consid
histori
infect
problemat
given
appar
persist
nipah
infect
singl
case
report
relaps
hendra
cn
lifetim
deferr
defens
virus
clinic
infect
outbreak
context
potenti
includ
travel
area
experi
signific
activ
donor
diagnos
one
viral
infect
seem
reason
blood
collect
organ
gener
procedur
guid
recal
cocompon
donat
expos
ill
donor
within
reason
interv
donat
would
reflect
incub
period
best
data
presenc
durat
put
viremia
would
prudent
perform
lookback
recipi
blood
transfus
recal
undertaken
purpos
assess
likelihood
infect
likewis
alleg
transfus
transmiss
care
evalu
need
evalu
donor
assess
appropri
studi
pathogen
reduct
labil
blood
product
publish
either
nipah
hendra
similar
virus
ie
envelop
rna
virus
effect
inactiv
process
advanc
approv
unit
state
likewis
one
would
expect
one
specif
viral
inactiv
remov
purif
step
commerci
plasma
fraction
process
would
elimin
risk
deriv
forego
depict
ad
hoc
process
recogn
respond
emerg
infecti
threat
transfus
safeti
whether
zoonot
arthropodborn
other
given
unpredict
attend
emerg
specif
pathogen
perhap
inevit
said
new
pathogen
emerg
axiomat
task
infecti
diseas
epidemiolog
expert
blood
commun
sensit
inevit
spend
real
effort
anticip
agent
mani
candid
pose
materi
threat
bear
forethought
plan
end
emerg
infect
subgroup
aabb
engag
develop
toolkit
guid
process
fig
critic
activ
horizon
scan
daili
surveil
spectrum
onlin
print
resourc
identifi
new
emerg
human
pathogen
includ
media
report
profession
meet
organiz
peerreview
public
open
sourc
subscript
websit
eg
prome
cdcgov
whoint
pahoorg
mani
other
person
network
perhap
difficult
element
horizon
scan
effect
hemovigil
requir
clinician
routin
elicit
transfus
histori
establish
differenti
diagnosi
patient
appar
infect
ask
four
question
propos
critic
imput
blood
vector
criteria
detail
review
includ
de
novo
identif
expans
rang
pathogen
especi
involv
outbreak
report
transmiss
organ
tissu
transplant
infect
follow
parenter
inocul
via
needl
stick
laboratori
accid
associ
inject
drug
use
sexual
activ
close
relationship
recogn
tti
actual
alleg
transfus
transmiss
role
effect
advanc
molecular
techniqu
eg
pathogen
discov
via
metagenom
nextgener
sequenc
nonculturebas
techniqu
studi
clinic
infect
patient
diagnost
indic
popul
includ
blood
donor
elucid
human
microbiom
explor
new
diseas
associ
yet
clear
fals
alarm
occur
member
normal
human
flora
discov
tt
viru
anelloviru
discov
use
represent
differ
analysi
amplif
nucleic
acid
patient
posttransfus
nona
b
c
hepat
caus
brief
consider
target
intervent
transfus
medicin
associ
ubiquit
viru
either
transfus
patholog
ill
eventu
refut
recent
nextgener
sequenc
appli
sera
us
patient
acut
liver
failur
unknown
etiolog
fail
identifi
unexpect
pathogen
suspicion
new
infect
threaten
blood
transfus
recipi
risk
must
quantifi
initi
use
provision
clinic
epidemiolog
descript
refin
time
onlin
risk
model
tool
accomplish
analys
develop
transfus
medicin
critic
obviou
caveat
precis
output
wholli
depend
input
paramet
necessarili
least
precis
earliest
stage
emerg
initi
prepared
decis
must
made
gener
specif
regard
transfus
safeti
critic
data
need
inform
quantit
assess
import
potenti
pathogen
routin
search
report
presenc
infecti
agent
imperfect
surrog
nucleic
acid
antigen
blood
asymptomat
individu
risk
would
valuabl
standard
oper
procedur
epidemiolog
investig
emerg
infect
often
occur
earli
blood
commun
must
respond
potenti
threat
likewis
prospect
determin
pathogen
surviv
contemporari
compon
product
process
storag
research
prioriti
conclud
materi
risk
may
present
intervent
must
consid
priorit
rang
inform
educ
donor
queri
deferr
exampl
would
ration
temper
world
consid
blanket
travel
deferr
sever
week
donor
visit
tropic
subtrop
venu
acut
arthropodborn
zoonot
agent
common
donor
test
determin
role
pathogen
reduct
techniqu
aggress
respons
greater
perceiv
risk
consider
necessarili
cyclic
iter
process
pivot
role
riskbas
decisionmak
societ
perspect
cover
elsewher
book
